This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on ISI (4)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Immunization  • Viral Infections  • Alert me on articles by topic

Brian Vastag

JAMA. 2004;291:549-550.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

While the World Health Organization is helping to contain another outbreak of Ebola hemorrhagic fever in West Africa—the fifth in two years—two vaccine candidates are raising hope that the world's deadliest virus will soon be tamed.

The first, a DNA "primer" containing DNA from the three known strains of Ebola virus, was injected into volunteers starting in November 2002. Its creators, mainly at the National Institutes of Health (NIH) envision it as stage one of a "prime-boost" strategy, with the booster using an adenovirus to smuggle additional Ebola virus DNA into antigen-presenting immune cells.

Scientists hope to develop vaccines that protect against Ebola virus (left). One novel vaccine candidate uses particles (right) that resemble Ebola virus's distinctive filaments; the particles form in cells engineered to produce two Ebola virus proteins. (Photo credit: Kelly Warfield, PhD, and Tom Larsen, PhD, USAMRIID)

Although DNA vaccines for various diseases have . . . [Full Text of this Article]